Lakewood-Amedex (LABT) news
Recent news
Priced: LBBW EUR 750M 2Y covered MS+7
AInvest Wire · 3d agoLakewood-Amedex Biotherapeutics - Bisphosphocin nu-3 phase 2A trial topline data expected Q1 2027
Lakewood-Amedex Biotherapeutics Inc. (NASDAQ: LABT) has initiated its Phase 2a clinical trial for Nu-3, a topically applied antimicrobial gel targeting mildly infected diabetic foot ulcers (iDFU). The trial, managed by contract research organization PERI, is evaluating three concentrations of Nu-3…
AInvest Wire · Oct 7, 2026Lakewood-Amedex Biotherapeutics announces positive data against recent clinical isolates from infected diabetic foot ulcers
AInvest Wire · Sep 28, 2026Lakewood-Amedex Biotherapeutics - Topline data from phase 2A nu-3 trial expected in Q1 2027
Lakewood-Amedex Biotherapeutics, Inc. has announced that it has received IRB approval and is preparing clinical sites to initiate Phase 2a trial of Nu-3 for the treatment of infected diabetic foot ulcers. The company has not yet disclosed the trial’s primary endpoints or detailed methodology but…
AInvest Wire · Sep 24, 2026Lakewood-Amedex Biotherapeutics announces first patient dosed in phase 2A clinical trial of NU-3 for infected diabetic foot ulcers
AInvest Wire · Sep 24, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.